cas 86770-80-1|| where to buy 3,3-difluorocyclobutane-1-carbonitrile

製品名:3,3-difluorocyclobutane-1-carbonitrile

IUPAC Name:3,3-difluorocyclobutane-1-carbonitrile

包装単位	有効在庫	価格（USD）
CM108791-10g	in stock	ƥǫȖ
CM108791-25g	in stock	ȅƃȯƥ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 86770-80-1 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:86770-80-1; 分子式:C5H5F2N; 融点:-; SMILESコード:N#CC1CC(F)(F)C1; 密度:

: カタログ番号:CM108791; 分子量:117.1; 沸点:; MDL番号:MFCD10001482; 保管方法:Store at 2-8°C.

: Cyclobutanes; The molecular structure of cyclobutane has four carbon atoms, and its four carbon atoms are not in the same plane, which is the folded conformation of cyclobutane. Cyclobutane itself is not of commercial or biological interest, but more complex derivatives are important in biology and biotechnology. Currently, nine FDA-approved drugs contain the cyclobutane structure. From the perspective of therapeutic areas, cyclobutyl drugs are mainly distributed in popular areas such as tumors, neurological diseases, infectious diseases, endocrine and metabolic diseases.

: Cyclanes; Cyclanes are secondary metabolites that can be found in plants, and are also biochemicals that can be used in medicine. Cyclanes are found in pine trees, and are used in the making of plastics. Cyclenes are found in cinnamon, and have antifungal properties.

: Fluorinated compounds; Fluorinated compounds refers to organic or inorganic compounds containing fluorine.

: Ivosidenib; Tibsovo (ivosidenib tablets) is a precision medicine that targets a specific type of mutation known as isocitrate dehydrogenase 1 (IDH1). Tibsovo is approved in five indications globally, including approvals in the U.S., European Union, Australia, and China.
Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation.
Fifth approved indication for Tibsovo solidifies Servier’s leadership in mutant IDH inhibition.